Vinod Jagannathrao Mokale

Vinod Jagannathrao Mokale

Auto-generated profile, based on publicly available information

Vinod Jagannathrao Mokale

University Department of Pharmaceutical Sciences, Mahatma Gandhi Mission University, Chhatrapati Sambhajinagar(Aurangabad), Maharashtra, 431001, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Journal of Industrial and Engineering Chemistry
Verified
Journal Article
Closed access
ASAkshara P. Shah
Akshara P. Shah
SJShilpa Jain
Shilpa Jain
VMVinod J. Mokale
Vinod J. Mokale
NSNavinchandra G. Shimpi
Navinchandra G. Shimpi

17 April 2015 in Journal of Experimental Nanoscience
Verified
Journal Article
Closed access
VMVinod J. Mokale
Vinod J. Mokale
HPHarshada I. Patil
Harshada I. Patil
APAjit P. Patil
Ajit P. Patil
PSPriyanka R. Shirude
Priyanka R. Shirude
JNJitendra B. Naik
Jitendra B. Naik
The aim of the study was to develop a proniosomal system for famotidine (FAM), a potent H2 receptor antagonist that could efficiently deliver entrapped drug over a prolonged period of time. The proniosomal system was formulated by selecting various ratios of Span 60 and cholesterol using a coacervation-phase separation method. The formulated systems were characterised for drug excipient compatibility studies by Fourier transform infrared spectroscopy (FTIR), vesicle size determination by the particle size analyser, % drug encapsulation, drug-release profiles, field emission scanning electron microscopy (FESEM) for surface morphology, X-ray diffraction (XRD) and vesicular stability at different storage conditions. By using this method, the % drug loading that resulted by the encapsulation of proniosome was found to be 78%–89%. Increase in cholesterol and surfactant concentration increases encapsulation efficiency, but further increment decreases encapsulation. In vitro drug-release studies showed prolonged release of entrapped famotidine. The highest % cumulative drug release was achieved in formulation FAM2 (96%) in 24 hours. The ex vivo data on the release of famotidine from proniosomal formulations have shown significantly increased per cent release and flux in comparison to the same dose of marketed preparation of famotidine. Stability studies were carried out in refrigerated conditions, and higher drug retention was observed. It is evident from this study that proniosomes are a promising prolonged delivery system for famotidine and have reasonably good stability characteristics.

1 February 2019 in Nano-Structures & Nano-Objects
Verified
Journal Article
Closed access
MLMadhuri Lakhane
Madhuri Lakhane
KBKashinath Bogle
Kashinath Bogle
RKRajendra Khairnar
Rajendra Khairnar
SDShailendra Dahiwale
Shailendra Dahiwale
RSRamphal Sharma
Ramphal Sharma
MMMegha Mahabole
Megha Mahabole

15 February 2026 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
AHAjinkya Shrirang Holkar
Ajinkya Shrirang Holkar
VMVinod Jagannathrao Mokale
Vinod Jagannathrao Mokale
Breast cancer remains one of the most frequently diagnosed malignancies worldwide and continues to represent a major public health concern despite substantial advances in diagnostic and therapeutic strategies. Conventional chemotherapy, although effective in many cases, is often associated with non-specific drug distribution, severe systemic toxicity, limited bioavailability, and the development of multidrug resistance. These limitations significantly compromise therapeutic outcomes and patient quality of life. Liposome-based drug delivery systems have developed as a highly promising nanotechnological approach to address these challenges by improving drug solubility, stability, circulation time, and tumor selectivity. Through rational design and surface functionalization, liposomes can be engineered to achieve passive and active targeting, controlled drug release, and reduced off-target effects. This review provides an expanded and original discussion of liposomal nanocarriers developed for targeted breast cancer therapy, covering formulation strategies, classification, targeting mechanisms, stimuli-responsive systems, clinical applications, current challenges, and future perspectives. Keywords: Liposomal nanocarriers; Breast cancer therapy; Targeted drug delivery; Nanomedicine; Stimuli-responsive systems; Precision oncology

30 September 2026 in Current Protein & Peptide Science
Verified
Journal Article
Closed access
PDF file
ASAsif Sayyad
Asif Sayyad
Bandoo ChataleBandoo Chatale
Bandoo Chatale
VMVinod Mokale
Vinod Mokale
Introduction: Protein aggregation is an issue that affects the stability and effectiveness of biopharmaceutical products. Proteins easily undergoes denaturation, due to mechanical agitation and prolonged storage times. Although polysorbates have been extensively used to stabilize proteins, there is still room to identify other highly effective additives. This research aimed to compare the efficacy of hydroxypropyl-β-cyclodextrin (HP-β-CD) in preventing protein aggregation in recombinant human insulin with polysorbate 20 (PS-20), polysorbate 80 (PS-80), and Poloxamer 188 (P188). Methods: Recombinant human insulin formulations with the addition of PS-20, PS-80, P188, or HP-β-CD, or the absence of any additive (control group), were prepared. The prepared samples were subjected to mechanical stress through shaking at 100 rpm for 24 hours. Thereafter, a sixmonth accelerated stability test was performed at 25±2°C/65±5% RH. Protein aggregation and particle formation were measured using size-exclusion high-performance liquid chromatography (SEHPLC) to detect HMWP, dynamic light scattering (DLS) for submicron aggregate size, and light obscuration (LO) of subvisible particles. Results: Mechanical agitation caused protein aggregation in all formulations; however, the degree of aggregation depended on the stabilizer used. HP-β-CD showed the highest stabilization activity, with only a 1.2% increase in HMWP level, whereas the non-stabilized control increased by 12.3%. LO analysis showed that formulations containing HP-β-CD had the least subvisible particles. In addition, DLS analysis showed no changes in aggregate size. Accelerated stability study results showed even better performance of HP-β-CD, with HMWP levels ranging from 2.60% to 2.64% over six months of storage, exceeding the performance of PS-20, PS-80, and P188. Discussion: The stabilization effect exerted by HP-β-CD could be assumed due to its capacity to decrease protein unfolding and prevent aggregation by the interfacial stress. Compared with the other surfactants, HP-β-CD provided better protection against mechanical and storage-related degradation of the protein while limiting particle formation. Conclusion: Under the conditions of agitation and storage stress, the use of HP-β-CD provides more efficient stabilization of recombinant human insulin as compared with polysorbate surfactants and Poloxamer 188.